RGLS

Regulus Therapeutics Inc. (RGLS) | Rumor.io

Regulus Therapeutics

RGLS

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about RGLS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 1

Regulus Therapeutics Inc. has solar and stellar alignments with Sirius, the Pleiades, and Fomalhaut.
There is no specific market or financial information about Regulus Therapeutics Inc. in the provided posts.
Regulus Therapeutics Inc. has been nominated for an award.

Generated by AI

Sentiment

Of the messages about RGLS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	97.36% +5.6
Bearish	—	—	—	2.64% -5.6

Bullish· Apr 30

Regulus Therapeutics Inc. (RGLS) has entered into an acquisition agreement with pharmaceutical giant Novartis for $7 per share, with potential for an additional $7 per share if regulatory milestones are met.
The acquisition is expected to provide a total equity value of up to approximately $1.7 billion, and has the potential to increase the stock price to $14 per share.
The deal is seen as a significant milestone for RGLS, which has been a long-term holding for some investors, and could potentially lead to a 500% increase in the stock price.

Bearish· Jan 29

The company's stock price has dropped 25% despite positive pre-market sentiment and a successful Phase-3 acceleration announcement.
The company's short sellers may experience significant losses due to a potential short squeeze.
The company's financial situation is questionable, with a 2-3 year cash runway and a history of burning through funds, which may raise concerns about its ability to finance Phase 3 trials.

Generated by AI

Topics

Of the messages about RGLS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	8.11%
Announcements	—	—	—	44.59%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	1.35%
Technical Analysis	—	—	—	45.95%

Earnings· Aug 9

Regulus Therapeutics Inc. (RGLS) beats earnings estimate by $0.03 and revenue estimate.
RGLS reports a loss of $0.13 per share, beating consensus estimate of ($0.16) per share.
RGLS beats Estimize EPS consensus by 2 cents and misses Estimize revenue consensus by $0.01 million.

Analysts· May 1

Regulus Therapeutics Inc. has been nominated for an award.
Analysts are likely to be impacted by this nomination.
The nomination is a positive development for the company.

Announcements· Mar 12

Regulus Therapeutics Inc. ($RGLS) raised $100m in an oversubscribed financing, with several institutional investors participating.
The company announced positive topline data from the second cohort of patients in its Phase 1b Multiple-Ascending Dose trial of RGLS8429 for ADPKD.
The data showed a dose response, with full results to be presented at 8:30, and the financing was completed at a premium to the company's market capitalization.

Technical Analysis· Mar 12

$RGLS broke cleanly above $3, reaching a 120% move, but then saw a quick sell-off.
The stock formed a potential bull flag on the 5-minute chart and a reversal is anticipated.
$RGLS bounced off the 2.20 trend line support and the 50 EMA at 1.99, indicating a possible continuation of the bullish trend.

Generated by AI

Community

Of the messages about RGLS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	48.5%
Newcomers	—	—	—	51.5%

Regulars· Mar 12

The oversubscribed financing of $RGLS includes prominent investors, and upon closing, the market may reward the company with positive price action.
The success of $RGLS's private placement may be linked to its positive data, and the new trend may be driven by the market's response to the data and financing.
$RGLS has announced positive topline data from its Phase 1b clinical trial, showing potential for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Newcomers· Jun 24

Regulus Therapeutics' $RGLS8429 shows promising results in Phase 1b trial for autosomal dominant polycystic kidney disease, with no safety concerns and a favorable safety profile.
The company's topline data from the Phase 1b trial is seen as positive, with investors watching for volume and the potential for the stock to take another run up after consolidation.
Regulus Therapeutics is set to meet with the FDA in Q4, with the company's next step being a meeting with the regulatory body after promising results in its clinical trial.

Generated by AI

Also Discussed

Investors talking about RGLS also mention

#	Name	Attention
1	Ionis Pharmaceuticals, Inc.IONS	0%new
2	Alnylam Pharmaceuticals, Inc.ALNY	0%0
3	Lakeland Industries, Inc.LAKE	0%0
4	Arrowhead Pharmaceuticals, Inc.ARWR	0%+0
5	TCON - TRACON Pharmaceuticals, Inc.	——
6	MRNS - Marinus Pharmaceuticals, Inc.	——
7	AFMD - Affimed N.V.	——
8	CMRX - Chimerix, Inc.	——
9	vTv Therapeutics Inc. Class A Common StockVTVT	0%new
10	Agios Pharmaceuticals, Inc.AGIO	0%0